| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| GRN Gene Therapy(Eli Lilly And Company) | PR-006; LY3884963 | Phase 2 Clinical | Eli Lilly And Company | Frontotemporal Dementia | 詳細 |
| TAK-594 | DNL-593; PTV:PGRN; TAK-594 | Phase 2 Clinical | Denali Therapeutics Inc | Frontotemporal Dementia | 詳細 |
| AVB-101 | AVB-101 | Phase 2 Clinical | AviadoBio Ltd | Frontotemporal Dementia | 詳細 |
| Nivisnebart | AL-101; GSK-4527226 | Phase 2 Clinical | Alector Inc | Alzheimer Disease; Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; Nerve Degeneration; Parkinson Disease | 詳細 |
| PBFT-02 | PBFT-02 | Phase 2 Clinical | University Of Pennsylvania | Frontotemporal Dementia | 詳細 |
| VGN-R13 | VGN-R13 | Phase 1 Clinical | Shanghai Vitalgen BioPharma Co Ltd | Amyotrophic Lateral Sclerosis | 詳細 |
| AG-01(A&G Pharm) | AG-01(A&G Pharm) | Phase 1 Clinical | A&G Pharmaceutical | Carcinoma, Non-Small-Cell Lung; Mesothelioma; Triple Negative Breast Neoplasms | 詳細 |